PharmaBlock Sciences announced the commissioning of its first peptide pilot-scale GMP plant at its Zhejiang manufacturing site in China. The facility supports client programs transitioning from early-stage R&D to pilot-scale GMP production.
Source: S&P Capital IQ / MarketScreener
The facility is equipped with a core cluster of solid-phase peptide synthesis (SPPS) reactors totaling 600 L (100 L, 200 L, and 300 L configurations), supporting production campaigns over 10 kilograms. It includes automated fluid handling, high-purity inert gas protection, two integrated cleavage systems, high-speed centrifuges, and 12-tray drying ovens.
The plant is zoned under Grade D and Class C cleanroom standards. Class C areas handle critical downstream steps including purification, lyophilization, and packaging. Beyond conventional SPPS, PharmaBlock's platform integrates LPPS (liquid-phase peptide synthesis), CF-LPPS (continuous-flow LPPS), and enzyme-assisted peptide synthesis (EAPS).